Fredun Pharmaceuticals Q1 Profit Rises 94.6% to ₹13.17 Crore

Fredun Pharmaceuticals Ltd reported Q1 FY27 net profit of ₹13.17 crore, up 94.63% year on year, while standalone total income increased 90.44% to ₹228.25 crore for the quarter ended June 30, 2026. The results set a high base ahead of the company's scheduled Q2 FY27 earnings review on November 5, 2026.

What did Fredun Pharmaceuticals report for Q1 FY27?

Fredun Pharmaceuticals reported strong growth across income, operating profit and net profit in Q1 FY27. Standalone total income rose from ₹119.86 crore in Q1 FY26 to ₹228.25 crore, while net profit increased from ₹6.77 crore to ₹13.17 crore. Revenue from operations was reported at ₹227.76 crore for the quarter.

EBITDA rose 92.90% year on year to ₹32.78 crore from ₹16.99 crore. The EBITDA margin improved by 18 basis points to 14.36%. The company approved the unaudited financial results for the quarter ended June 30, 2026, at its board meeting held on August 5, 2026.

How did the quarter compare with recent performance?

Fredun Pharmaceuticals' reported revenue of about ₹228 crore was higher than the ₹213 crore shown for the preceding March 2026 quarter in the supplied quarterly data. Net profit was about ₹13 crore, compared with ₹11 crore in that prior quarter, while operating profit rose to about ₹29 crore from ₹26 crore in the same comparison.

The company's quarterly sales have increased materially from ₹120 crore in June 2025 to ₹228 crore in June 2026. Operating profit in the same period moved from ₹17 crore to ₹33 crore in the longer quarterly results series. However, reported operating margin data show some variation across quarters, with margins ranging from 12% to 16% in the recent history provided.

Why is the pet-wellness strategy relevant to Fredun Pharmaceuticals?

Fredun Pharmaceuticals has announced its entry into India's pet-wellness market through the Furlicks acquisition from USV and Wellbeing Nutrition. The portfolio covers products for skin, gut, joint, calming and oral care, as well as multivitamins. The company has stated plans to introduce 44 new stock-keeping units, with 12 in the first phase and 32 in the second phase.

The company has also acquired Wagr.ai, a pet technology platform, and announced the acquisition of a 26% stake in Goodman Vetcare Pvt. These actions indicate that the pet-care initiative includes both product categories and related platform or veterinary capabilities. The source material does not provide financial contributions from these investments to Q1 FY27 revenue or profit.

What is the next reported event for Fredun Pharmaceuticals?

Fredun Pharmaceuticals' board was scheduled to meet on November 5, 2026, to consider and approve unaudited standalone and consolidated financial results for Q2 FY27 and the half year ended September 2026. The company had closed its trading window from October 1, 2026, until 48 hours after the results announcement, covering designated persons and their relatives.

The November board meeting follows the Q1 results approved on August 5, 2026. While some supplied material refers to results being declared on November 5, the stated financial figures in the source relate to Q1 FY27. The disclosed board-meeting notice identifies the November event as the review of Q2 FY27 and half-year results.

What do the figures mean for investors and operations?

The Q1 figures show that profit growth broadly kept pace with income growth. Total income increased 90.44%, EBITDA rose 92.90%, and net profit grew 94.63% from the year-earlier quarter. The 18-basis-point expansion in EBITDA margin provides a measured indication of operating leverage during the quarter.

The broader revenue base has also expanded. Fredun Pharmaceuticals' revenue increased from ₹454 crore in FY25 to ₹635 crore in FY26, according to the supplied information, while trailing-twelve-month revenue was cited at ₹639 crore. Management has stated a target growth rate of 25% to 30%, supported by expansion of the Freossi pet-care brand and own-brand exports, which account for 65% of export volume.

For investors, the November results will provide the next reported comparison point after the June quarter's ₹228.25 crore total income. For operations, the product rollout and acquired pet-care businesses are relevant because the company is adding new categories while continuing its established pharmaceutical and export activities.

Conclusion

Fredun Pharmaceuticals delivered a substantial Q1 FY27 increase in income and profit, with standalone total income reaching ₹228.25 crore and net profit reaching ₹13.17 crore. EBITDA growth of 92.90% and a modest margin improvement accompanied the revenue expansion, while the company continued building its presence in pet wellness through acquisitions and planned product launches.

The next disclosed event is the November 5, 2026 board meeting for Q2 FY27 and half-year financial results. Investors will be able to assess the pace of revenue growth after Q1, operating-margin movement and any further disclosures on the planned 44 pet-wellness stock-keeping units.